Expression system for modulating an immune response

Recombinant HCV E2 glycoprotein

Vaccine formulation potentiated by the combination of DNA and an antigen

Immunotherapy and prevention of autoimmune hepatitis

ANTI-HCV VACCINE AND PREPARATION METHODS AND USES THEREOF

Idiotypic vaccine

Vaccines comprising an immunostimulatory peptide and an immunostimulatory oligodeoxynucleic acid molecule

Peptide Derived from Hepatitis C Virus

CLONED GENOME OF INFECTIOUS HEPATITIS C VIRUS STRAIN HC-TN AND USES THEREOF

PRODUCTION AND USE OF EPITOPE-TAGGED HEPATITIS C VIRUS PARTICLE

Dendritic cell binding proteins and uses thereof

Chimeric flavivirus vaccines

VACCINES

Methods of promoting antitumor immunity by administering CD40 agonists and alpha-galactosyl ceramide

Neutralization of HCV

COMPOSITIONS AND METHODS FOR TREATING INTRACELLULAR DISEASES

Yeast-based therapeutic for chronic hepatitis C infection

Polypeptide fragments of the hepatitis E virus, the vaccine composition comprising said fragments and the diagnostic kits

COMPOSITIONS AND METHODS FOR CHITOSAN ENHANCED IMMUNE RESPONSE

Polypeptide fragments of the hepatitis E virus, the vaccine composition comprising said fragments and the diagnostic kits

Immunotherapy of virus infection

Hepatitis C virus codon optimized non-structural NS3/4A fusion gene

HCV neutralizing epitopes

PEPTIDES FOR INDUCING A CTL AND/OR HTL RESPONSE TO HEPATITIS C VIRUS

Hypo- and Hyper- Acetylated Meningococcal Capsular Saccharides

Detection and use of antiviral resistance mutations

Method and System for Optimizing Minigenes and Peptides Encoded Thereby

VACCINE COMPOSITIONS

Immunogenic Affinity-Conjugated Antigen Systems Based on Papaya Mosaic Virus and Uses Thereof

Immuno-Stimulant Combination for Prophylaxis and Treatment of Hepatitis C

Activation of HCV specific T cells

COMPOSITIONS AND METHODS FOR ELICITING AN IMMUNE RESPONSE TO ESCAPE MUTANTS OF TARGETED THERAPIES

Monoclonal antibody against hepatitis E virus or its fragment with binding activity and use thereof

Adjuvant compositions

HCV E1E2 vaccine compositions

Cloned genome of infectious hepatitis C virus strain HC-TN and uses thereof

VIRUS LIKE PARTICLES

RECOMBINANT MVA CAPABLE OF EXPRESSING STRUCTURAL HCV ANTIGENS

Chimeric Hepatitis C Virus Antigens For Eliciting an Immune Response

system and uses thereof

METHOD FOR ENHANCING THE EFFICACY OF ANTIGEN SPECIFIC TUMOR IMMUNOTHERAPY

HCV Vaccinations

Polynucleotide encoding HCV epitopes which can bind to various HLA supertypes, immunogenic composition comprising same and method of inducing an HCV-specific immune response using same

Manufacture of Vaccines That Contain Both Hepatitis B Virus Surface Antigen and Surfactant

HCV VACCINES

METHOD FOR TREATING TUMOR USING IRRADIATED TUMOR CELL EXPRESSING HUMAN HEPATITIS B SURFACE ANTIGEN AND A PHARMACEUTICAL COMPOSITION COMPRISING THE TUMOR CELL

HCV VACCINES

Use of microparticles combined with submicron oil-in-water emulsions

Pharmaceutical Composition Comprising An Antigen

Virosome particles comprising antigens from influenza virus and hepatitis b virus

Yeast-based therapeutic for chronic hepatitis C infection

Immunogen platform

Methods for generating immune response using cationic-liposome-mediated nucleic acid delivery

Hepatitis C virus nucleic acid vaccine

Modified Viral Particles with Immunogenic Properties and Reduced Lipid Content Useful for Treating and Preventing Infectious Diseases

MEDICINAL FORMULATION FOR THE TREATMENT FOR HEPATITIS C

Method for inhibiting HIV-1 replication utilizing anti-GBV-C E2 antibodies

Chloroplasts Engineering to Express Pharmaceutical Proteins

Modified Viral Particles with Immunogenic Properties and Reduced Lipid Content Useful for Treating and Preventing Infectious Diseases

Hepatitis-C virus type 4, 5 and 6

Inhibitors of hepatitis C virus

Adjuvant systems and vaccines

Method of Treating and Preventing Infectious Diseases via Creation of a Modified Viral Particle with Immunogenic Properties

Method of Treating and Preventing Infectious Diseases via Creation of a Modified Viral Particle with Immunogenic Properties

Hepatitis C virus codon optimized non-structural NS3/4A fusion gene

Hepatitis C virus vaccine

PURIFIED HEPATITIS C VIRUS ENVELOPE PROTEINS FOR DIAGNOSTIC AND THERAPEUTIC USE

Vaccine Composition Against Hepatitis C Virus

Supertype Epitopes, Oligonucleotides Coding The Same Which Induce Effective Ctl Response Against Hcv And The Use Thereof

Vaccination with immuno-isolated cells producing an immunomodulator

Yeast-based therapeutic for chronic hepatitis C infection

Eliciting HCV-specific antibodies

VACCINE COMPOSITION

Yeast-based therapeutic for chronic hepatitis C infection

HBV core antigen particles with multiple immunogenic components attached via peptide ligands

Alternate reading frame hepatitis C virus peptides and uses thereof

Pharmaceutical Compositions for Therapeutic Use

Composition comprising the polyprotein NS3/NS4 and the polypeptide NS5B of HCV, expression vectors including the corresponding nucleic sequences and their therapeutic use

Compositions Comprising Cationic Microparticles And Hcv B1e2 Dna And Methods Of Use Thereof

Method of treating and preventing infectious diseases

Immunomodulating compositions and uses therefor

Immunogenic lipopeptides comprising T-helper and cytotoxic T lymphocyte (CTL) epitopes

Hepatitis-C virus type 4, 5 and 6

Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use

Vaccine Comprising a Polysaccharide Antigen-Carrier Protein Conjugate and Free Carrier Protein

Microemulsions with adsorbed macromolecules and microparticles

Method for inducing hepatitis c virus (hcv) replication in vitro, cells and cell lines enabling robust hcv replication and kit therefor

Hepatitis C virus vaccine

HCV COMBINATION THERAPY

Flavivirus NS5A proteins for the treatment of HIV

Genetic immunization with nonstructural proteins of hepatitis C virus

Hcv vaccines

Hepatitis C virus non-structural NS3/4A fusion gene

Vaccine-induced hepatitis B viral strain and uses thereof

Particles of HCV envelope proteins: use for vaccination

Modified HCV peptide immunogens

Vaccines

Monoclonal antibody against hepatitis E virus or its fragment with binding activity and use thereof

Infectious hepacivirus pseudo-particles containing functional e1, e2 envelope proteins

Compositions and methods for delivery of genetic material

Hepatitis C virus codon optimized non-structural NS3/4A fusion gene

Vaccines containing ribavirin and methods of use thereof

Sphingoid polyalkylamine conjugates for Hepatitis B virus vaccination

Method for inducing complete hepatitis c virus (hcv) replication in vitro

Combination gene delivery vehicles

Yeast-based therapeutic for chronic hepatitis C infection

Peptides for inducing a CTL and/or HTL response to hepatitis C virus

Inhibitors of hepatitis C virus

Hepatitis C virus non-structural NS3/4A fusion gene

Helicobacter system and uses thereof

Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus

ADAR1 antiviral pathway

Methods for tailoring the immune response to an antigen or immunogen

Vaccination with immuno-isolated cells producing an immunomodulator

Method of generating recombinant MVA

Vaccine enhancing the protective immunity to hepatitis c virus using plasmid DNA and recombinant adenovirus

Enhancing immune responses to genetic immunization by using a chemokine

HCV E1E2 vaccine compositions

Hepatitis-C virus type 4, 5 and 6

Pharmaceutical composition comprising an antigen

Use of microparticles combined with submicron oil-in-water emulsions

Vaccine comprising a polysaccharide antigen - carrier protein conjugate and free carrier protein

Modified HCV peptide vaccines

Hepatitis C virus codon optimized non-structural NS3/4A fusion gene

GB virus C (hepatitis G virus) for the treatment of HIV

Human hepatoma lines, methods for obtaining same and uses thereof

Thymosin augmentation of genetic immunization

Method of treating viral infections

Vesiles derived from t cells, production and uses

HCV combination therapy

Modified viral particles with immunogenic properties and reduced lipid content

Hepatitis-C virus type 4, 5, and 6

Recombinant mva capable of expressing structural hcv antigens

Transient expression of biologic materials